Herceptin acts as an anti-angiogenic cocktail

Yotaro Izumi, Lei Xu, Emmanuelle di Tomaso, Dai Fukumura and Rakesh K. Jain ()
Additional contact information
Yotaro Izumi: Edwin L. Steele Laboratory, Massachusetts General Hospital, Harvard Medical School
Lei Xu: Edwin L. Steele Laboratory, Massachusetts General Hospital, Harvard Medical School
Emmanuelle di Tomaso: Edwin L. Steele Laboratory, Massachusetts General Hospital, Harvard Medical School
Dai Fukumura: Edwin L. Steele Laboratory, Massachusetts General Hospital, Harvard Medical School
Rakesh K. Jain: Edwin L. Steele Laboratory, Massachusetts General Hospital, Harvard Medical School

Nature, 2002, vol. 416, issue 6878, 279-280

Abstract: Abstract Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules1,2, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin3, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.

Date: 2002
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/416279b Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:416:y:2002:i:6878:d:10.1038_416279b

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/416279b

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().